ACAT1 and non-small cell lung carcinoma: Acat1 knockdown improved B cell and TLS abundance and increased the sensitivity of NSCLC cells to anti-PD1 immunotherapy, providing metabolic-intervention ideas for improving NSCLC immunotherapy.